文献速递妇科生殖医学

复方口服避孕药与二甲双胍对PCOS患者生活质量、情绪及性功能的影响

Health-Related Quality of Life, Mood, and Sexual Function in Polycystic Ovary Syndrome (PCOS): Assessing the Impact of Combined Oral Contraceptive Pills and Metformin Therapy (characters with spaces: 175, limit 125).
PubMed 文献 · Fertil Steril · 2026-10-19

本研究为COMET-PCOS随机对照试验的二次分析,纳入240例21-40岁、BMI≥25 kg/m2的高雄激素性多内分泌代谢性卵巢综合征(PMOS)女性,比较复方口服避孕药(COCP)、二甲双胍及联合治疗6个月对健康相关生活质量、抑郁、焦虑及性功能的影响。结果显示三种治疗对心理健康和生活质量均有改善或中性效应,二甲双胍改善抑郁症状和焦虑,COCP轻度降低性欲但不增加性困扰或性功能障碍。

要点

  • 二甲双胍可改善高雄激素性PMOS伴BMI升高女性的抑郁症状和焦虑。
  • COCP轻度降低性欲评分,但不增加性困扰或性功能障碍发生率。
  • 联合治疗对生活质量各领域均有改善,为临床咨询提供依据。

核心结论

  • COCP和二甲双胍对高雄激素性PMOS伴BMI升高女性的心理健康和生活质量呈有利或中性效应。
  • 二甲双胍改善抑郁症状和焦虑,COCP轻度降低性欲但不增加性困扰或性功能障碍。

研究设计与样本

  • COMET-PCOS双盲、双模拟、平行随机对照试验的二次分析。
  • 240例21-40岁高雄激素性PMOS且BMI≥25 kg/m2的女性,随机接受COCP、二甲双胍或联合治疗,分析限于基线和研究终点均有应答者。

主要发现

  • 联合组(n=60)mPCOSQ所有领域评分较基线改善(p<0.01)。
  • COCP组(n=56)mPCOSQ除月经健康和痤疮领域外改善(p<0.01)。
  • 二甲双胍组(n=51)mPCOSQ除体毛和体重领域外改善(p<0.05)。
  • 抑郁症状和抑郁患病率在COCP组和联合组无变化,二甲双胍组改善(p<0.001)。
  • 状态焦虑在二甲双胍组和联合组改善(p<0.01),特质焦虑在所有组改善(p<0.05)。

关键数值与推荐

  • COCP组FSFI欲望领域评分较低(p<0.001),唤醒领域较低(p=0.03),总分无差异(p=0.07)。
  • 性困扰在COCP组(p=0.03)和二甲双胍组(p=0.03)均降低。
  • 任何组性功能障碍患病率均无显著变化。

临床怎么用

  • 可为高雄激素性PMOS伴BMI升高女性提供COCP和二甲双胍对心理及性健康影响的咨询。
  • 二甲双胍可能有助于改善抑郁症状和焦虑。
  • COCP对性欲有轻度降低作用,但不增加性困扰或性功能障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the effects of combined oral contraceptive pills (COCPs), metformin, and their combination on health-related quality of life, depression, anxiety, and sexual function in women with hyperandrogenic polyendocrine metabolic ovarian syndrome (PMOS) and elevated BMI. DESIGN: Secondary analysis of a double-blind, double-dummy, parallel, randomized controlled trial (COMET-PCOS). SUBJECTS: 240 women aged 21-40 years with hyperandrogenic PMOS and BMI ≥25 kg/m2, randomized to COCP, metformin, or COCP+metformin; analyses were subset to subjects with a response at both baseline and end of study. INTERVENTION: Six months of COCP (20μg ethinyl estradiol/0.15 mg desogestrel), metformin XR 2000 mg/day, or combination therapy. MAIN OUTCOME MEASURES: Changes from baseline to study end in modified PCOS Health Related Quality of Life (mPCOSQ) domains, Center for Epidemiologic Studies Depression Scale (CES-D), State-Trait Anxiety Inventory (STAI Y-1 and Y-2), Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS). RESULTS: Compared to baseline, mPCOSQ scores improved across all domains in the combination group (n=60, p<0.01), COCP group (n=56, p<0.01, except menstrual health and acne domains), and metformin group (n=51, p<0.05, except body hair and weight domains). Depressive symptoms and depression prevalence were unchanged in the COCP and combined group but improved in the metformin group (p<0.001). State anxiety improved in the metformin and combined groups (p<0.01); trait anxiety improved across all groups (p<0.05). FSFI scores were lower in the COCP group for the desire (p<0.001) and arousal (p=0.03) domains with no difference in total score (p=0.07); however, sexual distress decreased in both the COCP (p=0.03) and metformin groups (p=0.03). There were no significant changes in the prevalence of sexual dysfunction in any group. CONCLUSION: Although COCPs and metformin are commonly used to manage PMOS, limited data exist on their impact on mental and sexual health. Our study demonstrates favorable or neutral effects of these therapies on mental health and quality of life in women with hyperandrogenic PMOS and elevated BMI. Metformin improved depressive symptoms and anxiety, while COCPs produced modest reductions in sexual desire without increasing sexual distress or dysfunction. These findings provide clinically relevant data for counseling women with PMOS, a group at high risk for mental health disorders.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Satish S, Ewy J, Coutifaris C, et al. Health-Related Quality of Life, Mood, and Sexual Function in Polycystic Ovary Syndrome (PCOS): Assessing the Impact of Combined Oral Contraceptive Pills and Metformin Therapy (characters with spaces: 175, limit 125). Fertil Steril. 2026. PMID: 42896751. doi:10.1016/j.fertnstert.2026.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。